1. Introduction {#S1}
===============

Protein tyrosine kinases and protein tyrosine phosphatases (PTPs) play essential roles in regulating signal transduction in multiple cell types by tyrosine phosphorylation and dephosphorylation, respectively. PTPs include non-receptor-type PTPs and receptor-type PTPs (RPTPs), which are vital cell surface proteins that have intracellular tyrosine phosphatase activity and extracellular domains with sequence homology to cell adhesion molecules. In contrast to the well-studied protein tyrosine kinases, the properties of most RPTPs remain less clear, including their specific substrates, regulation, biological functions and possible roles in human disorders ([@R30]; [@R86]). The RPTP family includes eight sub-families based on their extracellular domain structures. Among them, type IIa RPTPs include three members in vertebrates, the leukocyte common antigen-related (LAR), PTPσ, and PTPδ. These RPTPs contain typical cell adhesion Ig and fibronectin III domains, which contribute to their interactions with the extracellular matrix (ECM) molecules. Structurally, RPTPs have two cytoplasmic tandem regions, the membrane-proximal PTP domain (D1, catalytically active) and the membrane-distal PTP domain (D2, inactive) ([@R86]). Additional splicing of small exon segments contributes to the structural diversity of the ectodomain ([@R69]).

During development, LAR and PTPσ are widely expressed by multiple tissues including the nervous system, lung, kidney and thymus, while PTPδ is more restricted in the nervous system ([@R73]; [@R76]; [@R84]; [@R101]; [@R115]). In mammalian nervous system, type IIa RPTPs (LAR, PTPσ, and PTPδ) are important for regulating synaptogenesis ([@R86]; [@R95]), especially formation of excitatory synapses by interacting with postsynaptic netrin-G ligand-3 (NGL-3) ([@R46]). The type IIa RPTPs are also expressed in adult nervous system, but their functional significance is not known completely. Deleting each of these RPTPs shows distinctive morphological and functional phenotypes in the nervous system of adult mice ([@R42]; [@R57]; [@R94]; [@R93]; [@R109]). Among these three RPTPs, LAR and PTPσ have been shown to be important functional receptors that bind chondroitin sulfate proteoglycans (CSPGs) with high affinity and mediate their inhibitory effects through the convergent and divergent signaling pathway ([@R20]; [@R62]; [@R63]; [@R74]). Following CNS injury, severed axons fail to regenerate in adult mammalians partly due to upregulation of various inhibitory ECM molecules around the lesion, especially the potent axon growth inhibitors of CSPGs. Whether PTPδ functions as a receptor of CSPGs remains to be determined.

Multiple PTPs are expressed preferentially in the haematopoietic system and some of them have been implicated in regulating development and functions in the immune system ([@R66]). Altered PTP activities may induce inappropriate proliferation, survival and activation of immune cells, and contribute to pathophysiology of inflammation and autoimmunity diseases. Thus, PTPs have the complex and diverse functions in the immune system and may become molecular targets for treating immune related disorders. Out of the three type-IIa RPTPs, LAR is expressed on immature thymocytes although its phosphatase activity appears unnecessary for T cell development and function ([@R43]; [@R90]). LAR and PTPσ are specifically co-expressed in murine plasmacytoid dendritic cells (pDCs) and deletion of both simultaneously increases interferon production by pDCs ([@R9]). Recently, we demonstrate that PTPσ is expressed in multiple immune cells, including DCs, and is critical for regulating their activation, cytokine production and immune-mediated inflammation ([@R64]). Because PTPσ is highly expressed in both nervous and immune systems and has crucial functions in both systems, this review will focus on the diverse functions of PTPσ and its related genes, and their significance in mediating neurological and autoimmune disorders.

2. RPTPs regulates neuronal growth and synapse formation during development {#S2}
===========================================================================

Three type-IIa RPTPs show divergent distribution patterns in the developmental nervous system. PTPσ is widely expressed throughout the central and peripheral nervous system during embryonic development. The high levels of its mRNA are especially detected in several structures, including ventricular and subventricular zones, cortex, dorsal root ganglia (DRG), cranial nerve ganglia, olfactory epithelium, and retina ([@R101]). During postnatal development, its expression levels decrease in most brain regions, although certain areas still exhibit high levels, such as hippocampus. In contrast, LAR mRNA is expressed in neural and non-neural tissues with different patterns from PTPσ. High levels of LAR mRNA are detected in epithelial layer of various embryonic tissues and in neuroepithelium and DRGs during embryogenesis. LAR expression shows developmental regulation during neural cell growth and differentiation ([@R53]). During embryonic development, PTPδ expression is relatively low and limited to differentiated cells of several structures, including olfactory bulb, cortical plate, thalamic nuclei, and olivary nucleus ([@R73]; [@R84]).

RPTPs are localized to the growth cone at axonal tip of immature neurons, while they are largely localized to the dendritic spines and excitatory synapse of mature neurons ([@R105]). RPTPs are localized to distinct types of synapses. In culture hippocampal neurons, PTPσ-immunostained puncta overlapped with the axonal vesicular glutamate transport protein 1, indicating its localization to CNS axons ([@R87]). LAR is concentrated in mature synapses in hippocampal neuronal cultures, and is vital for development and maintenance of excitatory synapses. LAR knockdown causes loss of excitatory synapses and dendritic spines, decrease of surface AMPA receptors, impaired dendritic targeting of cadherin-beta-catenin complex and dysfunction in excitatory synapses ([@R19]; [@R103]). In contrast, in addition to expression in excitatory synapses, PTPδ accumulates in inhibitory presynapses and regulates their genesis by interacting with postsynaptic adhesion molecule Slit and Trk-like family proteins 3 (Slitrk3) ([@R88]). Thus, individual RPTPs appear to target different synapse types probably by binding to diverse ligands in distinct types of synapses.

RPTPs, including PTPσ and LAR, mediate various cell-ECM adhesions by binding some extracellular ligands, such as heparan sulfate proteoglycans (HSPGs) and CSPGs ([@R2]; [@R14]; [@R34]). HSPGs are the cell-surface and ECM glycoproteins usually containing one or more covalently attached heparan sulfate (HS) chains, a type of glycosaminoglycan (GAG). CSPGs are a diverse family of ECM molecules characterized by containing chondroitin sulfate (CS) chains. Each of the HSPGs and CSPGs comprises of a core protein and a variable number of highly sulfated GAG side chains frequently with negative charge. GAGs are long unbranched polysaccharides with repeating disaccharides, which comprise an amino sugar (*N*-acetylglucosamine or *N*-acetylgalactosamine) along with a uronic sugar (glucuronic acid or iduronic acid) or galactose. GAGs are classified into CS, HS, hyaluronic acid, dermatan sulfate, and keratan sulfate based on their component sugars. CS chains contain *N*-acetylgalactosamine and glucuronic acid in contrast to *N*-acetylglucosamine and glucuronic acid in HS chains. RPTPs interact with ECM molecules by binding the GAG chains of proteoglycans ([@R17]; [@R20]; [@R74]). PTPσ binds to CS-D, CS-E, and DS, but not to CS-A or CS-C ([@R17]). Recently, Geller's group demonstrated that the main binding sites for PTPσ are located to neurons in adult mouse brain, but are not to GAG chains of proteoglycans ([@R110]). Further studies are required to clarify these discrepancies.

The highly-controlled sulfation patterns on CS chains are important for mediating CSPG functions ([@R58]; [@R114]) although various studies revealed inconsistent results on the roles of different CS chains. CS-E, not CS-A, could suppress outgrowth of both cerebral cortical and DRG neurons ([@R7]; [@R11]; [@R37]; [@R97]), but CS-E was also reported to promote neurite growth of hippocampal and cortical neurons ([@R70]; [@R92]). CS-C was either inhibitory or non-inhibitory to neurite growth reported by different groups ([@R7]; [@R11]). In contrast, CS-A, not CS-C, was found inhibitory to neurite growth of cerebellar granule cells ([@R102]). Therefore, it will be important to further elucidate the spatiotemporal regulation and precise functions of various CS chains, their specific molecular interactions and downstream signaling pathways.

CS and HS chains share common uronic sugar residues (glucuronic acid and iduronic acid) and a linkage region of xylose--galactose, but they consist of different amino sugar disaccharides, the *N*-acetylgalactosamine for CS and the *N*-acetylglucosamine for HS added by distinct enzymes ([@R52]; [@R114]). CSPGs and HSPGs regulate growth, guidance, and connections of CNS neurons, but these two subclasses of sulfated proteoglycans have distinct functions on neuronal growth, typically with suppression by the former and promotion by the latter on axonal elongation ([@R3]; [@R14]; [@R77]). Presence of CSPGs remarkably attenuated neurite outgrowth of cultured DRG neurons ([@R18]; [@R81]; [@R80]). In contrast, treatment with HSPGs, including glypican-2, strongly promoted elongation of cultured neurons *in vitro* ([@R14]; [@R31]; [@R48]).

HSPGs and CSPGs regulate axon growth during development through their HS or CS chains. HS treatment induced axon defasciculation and growth in incorrect directions in cultured cockroach embryos, while CS treatment had no effect. Enzymatic degradation of HS by heparitinase resulted in axon perturbation, whereas degradation of CS had no effect ([@R100]). Similarly, heparin, a glycosaminoglycan containing heparan sulfate, resulted in abnormal axon behavior in retinal ganglion cells from *Xenopus laevis* embryos ([@R99]). CSPGs also play a remarkable role in guiding axons by forming inhibitory areas during development. CSPG expression shows precise spatial and temporal pattern in developing retina. CSPG was detected during retinal development of rat at embryonic day 12.5 (E12.5), gradually decreased from the central area to the periphery, and no longer detectable at E17 ([@R1]). Treatment of cultured embryonic retina with chondroitinase ABC (ChABC) to remove CS GAG chains induced abnormal retinal axon projections into the region where normal axons could not enter ([@R82]). Therefore, proteoglycans regulate axon guidance and extension during development probably by interacting with RPTPs, including PTPσ.

RPTPs play an important role in mediating synapse formation during development. Based on the expression patterns and phenotypes in transgenic animals, PTPσ and PTPδ appear to play more important roles than LAR for synapse organization during development. Functional interactions of RPTPs with a number of postsynaptic binding partners generate a complicated synaptic network and control synapse formation. Presynaptic RPTPs form trans-synaptic adhesion complexes with multiple postsynaptic adhesion molecules ([Fig. 1A](#F1){ref-type="fig"}), including NGL-3 ([@R46]; [@R103]), neurotrophin receptor TrkC ([@R87]), interleukin-1 (IL1) receptor accessory protein-like 1 (IL1RAPL1) ([@R96]; [@R112]), its paralog IL1RAPL2 ([@R65]; [@R96]; [@R112]), IL-1 receptor accessory protein (IL-1RAcP) ([@R113]), and Slitrks ([@R88]; [@R111]). Though all three type-IIa RPTPs can bind to NGL-3 through their first two FNIII domains and also to IL-1RAcP, Slitrks bind to PTPσ and PTPδ selectively through the Ig domains. In contrast, TrkC binds to PTPσ and IL1RAPL1 binds to PTPδ only.

Axonal RPTPs accumulate NGL-3 on dendrites and appear to promote excitatory postsynaptic development by interactions with NGL-3 and postsynaptic density protein (PSD-95). NGL-3 mainly induced excitatory presynaptic differentiation of contacting axons in co-cultured system and this effect is suppressed by treatment with soluble LAR ectodomain ([@R103]). Induced aggregation of NGL-3 on dendrites resulted in dendritic clustering of excitatory, but not inhibitory, postsynaptic proteins, including the scaffold protein PSD-95. Accordingly, the C-terminus of NGL-3 has been shown to bind the PDZ domains of PSD-95 ([@R41]). Although all three type IIa RPTPs can bind and interact with NGL-3, PTPσ appears to be the main pre-synaptic component based on their exclusive excitatory synaptic localization, affinity for NGL-3 and expression pattern in the brain.

Presynaptic PTPσ interacts with postsynaptic TrkC and seems to regulate development of excitatory synapses transduced by the intracellular domain of PTPσ. Trks, a family of tyrosine kinases, are well characterized as the receptors of neurotrophic factors that control neural survival, differentiation, proliferation, the fate of neural precursors, axon and dendrite growth and patterning. With unbiased expression screen in co-culture system, PTPσ, but not PTPδ and LAR, was identified as a TrkC binding partner ([@R87]). Moreover, TrkC induced excitatory, but not inhibitory, presynaptic differentiation and this effect is abolished by axonal expression of mutated PTPσ lacking the intracellular region.

RPTPs promote excitatory synapse development also by interacting with members in the IL-1/Toll receptor family (IL1RAPL1, IL1RAPL2 and IL1RAcP) and activating PSD-95 and Jun-N-terminal kinase (JNK) signaling pathways. IL1-RAcP interacts with all three type IIa RPTPs, although IL1RAPL1 binds PTPδ, but not PTPσ and LAR. IL1RAPL1-PTPδ interactions recruited GTPase-activating protein to regulate excitatory synapse formation, as well as dendritic synapse number and morphogenesis ([@R96]; [@R112]). IL-1RAcP includes two isoforms, the ubiquitously-expressed IL-1RAcP and the CNS-specific IL-1RAcPb ([@R79]). Both isoforms regulate differentiation of excitatory presynapses, while IL-1RAcPb also contributes to formation of dendritic spines. Because IL-1RAcP interacted with PTPδ through the extracellular domain and the IL-1RAcP-mediated formation of presynapses is partly abolished in cortical neurons derived from PTPδ-deficient mice ([@R113]), the interactions of IL-1RAcP with other RPTPs, such as PTPσ and/or LAR, may also play a significant role in this action. Given that IL1RAPL1-dificient neurons have reduced levels of phosphorylated PSD-95 and JNK proteins, these signaling pathways appear to mediate the RPTP-IL1RPL1 interactions ([@R65]).

Slitrks play important roles in regulating synapse development by forming protein complex with RPTPs ([@R111]). Slitrks are a family of transmembrane receptors that contain six leucine-rich repeat domains. All six members (Slitrk1--6) are able to induce presynaptic differentiation in neuronal co-cultures. Five Slitrks, except for Slitrk3, could interact with PTPσ and contribute to excitatory synaptogenic activities. Only Slitrk3 can induce inhibitory, but not excitatory, pre-synaptic differentiation *in vitro* and *in vivo* by interact with presynaptic PTPδ ([@R88]). Of note, because CSPG plays an important role in restricting neuronal plasticity following injury, interactions of RPTPs with postsynaptic adhesion molecules during development may also be regulated by competing with CSPGs in a spatiotemporal manner.

3. PTPσ mediates neuroplasticity in mature neurons {#S3}
==================================================

Although a number of brain regions show obvious mRNA distribution of PTPσ, LAR and PTPδ in the adult mice, their expression patterns are very diverse ([@R73]; [@R76]; [@R101]). During postnatal development, the expression level of PTPσ decrease dramatically in most brain regions, but high levels continue to be detected in hippocampus, especially the pyramidal cell layer ([@R46]). Strong signals for PTPσ are also detected in several other areas of adult mammals, including the internal granule layer of olfactory bulb, piriform cortex, tenia tecta, septal area and cerebellum. Strong LAR signals are found in the internal granule layer of olfactory bulb, subventricular zone of caudate putamen and cerebellum, but are less abundantly in layer IV of cortex and septal area. In contrast, PTPδ protein or mRNA is expressed in the hippocampus (particularly the CA2 and CA3 regions), layer IV of cortex, granule cell layer of cerebellum, thalamic nuclei, and mitral and granular cell layers of the olfactory bulb, but it is undetectable in septal area. Therefore, three type IIa RPTPs exhibit overlapping, but differential distribution patterns in the developed brain.

PTPσ modulates the neuronal plasticity in mature neurons. PTPσ-deficient mice exhibit severe growth retardation, high neonatal mortality and neurological deficiencies, including thinning of the corpus callosum and cerebral cortex, hippocampal dysgenesis, abnormal pituitary development, motor dysfunction and defective proprioception ([@R57]; [@R94]). PTPσ null mice also have increased hippocampal mossy fibers and axon sprouting during aging, consistent with PTPσ limiting synapse formation. PTPσ deficiency increases the frequency of miniature post-synaptic currents mediated by α-amino-3-hydroxy5-methyl-4-isoxazolepropionic acid (AMPA) receptor, accompanied by an increase in synapse density, but decreases synaptic efficiency. Moreover, the role of PTPσ in CNS plasticity has been demonstrated in learning and memory. PTPσ null mice show reduced long-term potentiation (LTP, an activity-dependent synaptic plasticity) in hippocampal Schaffer collateral-CA1 synapses and enhanced performance in a novel object recognition memory test ([@R33]).

LAR deficient mice have smaller basal forebrain cholinergic neurons and reduced cholinergic innervation of their target neurons in the dentate gyrus ([@R109]). Mice lacking the phosphatase domains of LAR have spatial learning deficiency and hyperactivity ([@R42]). PTPδ knockout mice also exhibit marked motor dysfunction, impaired visuospatial processing with low survival rates ([@R94]; [@R93]), and impaired learning and memory tasks and enhanced LTP ([@R93]). The phenotype differences in deficiency of three RPTPs may result from diverse ligands, subcellular distribution or downstream signaling pathways.

PTPσ regulates synaptic plasticity, learning and memory in adult CNS, but it is unclear whether its function is associated with the interactions with perineuronal nets (PNN) molecules, especially CSPGs. PNNs are composed of ECM macromolecules (including hyaluronan, CSPGs, tenascin-R, link proteins and other components) and organize these molecules into specific structures ([@R10]; [@R29]; [@R45]; [@R55]). In extracellular space, CSPGs interact with HA polymer on cell surface and induce a stable connections with HA polymer chains and other linked proteins. The C-terminal domains of CSPG core proteins bind tenascin-R to form highly organized constructions of PNNs. PNNs wrap the neuronal cell body, proximal dendrites and synapses of various neuronal populations. CNS starts to form PNNs in the late stage of development, especially during critical periods of synaptic maturation ([@R45]). PTPσ is one of the two identified RPTP receptors for CSPGs, the major components of PNN ([@R74]), but Geller's group did not detect PTPσ binding to PNN in the mouse brain ([@R110]). Further studies are required to illustrate the molecular mechanisms for PTPσ-mediated neuronal plasticity.

PNNs may play critical roles in the mature CNS, including synapse stabilization, neuroprotection, ionic buffering and neuronal plasticity. PNNs have been implicated to maintain and modify cognition, learning and memory functions. PNN formation in amygdala of mice affects developmental shift in the ability to erase fear memories by extinction ([@R27]). Organization of CSPGs in PNNs mediates formation of erasure-resistant fear memories because local treatment of amygdala with ChABC to digest CSPGs in adult mice re-enabled the subsequent erasure of fear memories by extinction. PNNs also play critical roles in controlling neuronal plasticity in hippocampus. Deficiency of PNN structures in transgenic mice shows reduced LTP by theta-burst stimulation in CA1 region of hippocampus. Pretreatment of cultured hippocampal slices with ChABC induces similar reduction of LTP *in vitro* ([@R8]). Deletion of brevican, one of brain-specific CSPGs, in mutant mice, or treatment of wild-type mice with anti-brevican antibody resulted in impaired LTP, although they exhibited normal behavior and spatial memory ([@R6]).

4. PTPσ functions as a CSPG receptor to mediate axon regeneration in the CNS {#S4}
============================================================================

After CNS injuries, reactive astrocytes generate extremely high levels of CSPGs, which potently suppress axon growth into and beyond the lesion area ([@R5]; [@R10]; [@R35]). The major CSPGs expressed in the CNS include lecticans (neurocan, versican, aggrecan, and brevican), phosphacan and NG2. Lecticans share many similar domains at both N- and C-termini of the core proteins and their core proteins are linked by a central CS-GAG anchoring backbone bound one or numerous long chain CS-GAG polysaccharide ([@R108]). Lecticans function as linkers of the ECM molecules. Phosphacan is the extracellular domain of transmembrane RPTPβ. NG2 is a transmembrane CSPG and has no significant homologies to other CSPGs. Because removing GAGs or preventing their sulfation neutralizes most suppression of axon growth by CSPGs *in vitro* ([@R26]; [@R75]; [@R102]), the sulfated GAG chains play crucial roles for CSPG function. CSPGs has been known to impede axon elongation for almost three decades, but the detailed mechanisms are not well known. The general mechanisms identified include binding functional CSPG receptors on neuronal membrane, formation of non-permissive PNNs that causes steric hindrance of growth-promoting adhesion molecules such as laminin and integrins, and facilitating functions of chemo-repulsive molecules, such as Sema 3A and 5A ([@R16]; [@R36]; [@R89]). Transmembrane receptors appear important in conveying CSPG inhibition, including PTPσ, LAR, and Nogo receptors 1 and 3 ([@R17]; [@R20]; [@R49]; [@R74]; [@R107]). Especially, PTPσ and LAR bind CSPGs with high affinity and convey their inhibitions of axon extension after CNS injury.

CSPG neurocan can bind and interact with PTPσ through the CSPG GAG chains and a few positively-charged residues in the first Ig-like domain of PTPσ ([@R74]). DRGs derived from PTPσ deficient mice increased neurite growth on CSPG and this effect was specific to CSPG because PTPσ deletion does not overcome suppression of myelin-associated glycoprotein. PTPσ knockout mice showed regeneration of lesioned ascending sensory neurons into the CSPG-rich lesion area although regenerating axons failed to pass injured area ([@R74]). Corticospinal tract (CST) axons regrew into and beyond the lesion area in adult PTPσ knockout mice after spinal cord injury (SCI) ([@R22]). Consistently, PTPσ knockout mice exhibited enhanced regeneration of optic nerve and peripheral nerve after injury ([@R56]; [@R72]; [@R91]). Moreover, PTPσ plays a crucial role in converting growth cones into a dystrophic state by tightly stabilizing them within CSPG substrates. Systemic treatment with a membrane permeable peptide mimetic of the PTPσ wedge domain, which regulates a variety of downstream signaling, restored extensive serotonergic innervation to the spinal cord caudal to lesion and promoted recovery of locomotor and urinary functions in adult rats with contusive SCI ([@R49]).

Similarly, CSPGs bind LAR dose-dependently also through CSPG GAG chains and the first Ig-like domain of LAR. LAR inhibition by transgenic deletion or pharmacological blockade with sequence-targeting blocking small peptides stimulated regrowth of serotonergic and CST axons, and functional recovery after transection SCI ([@R20]; [@R107]). As another member of type IIa RPTPs, whether PTPδ also mediates CSPG suppression as a transmembrane receptor is unknown. However, PTPδ has recently been reported to contribute to Semaphorin-3A mediated growth cone collapse response in neuronal cultures probably by dephosphorylating tyrosine residues at the C-terminus of Fyn and activing this kinase ([@R61]). Notably, Semaphorin-3A is a component of PNN together with CSPGs and is able to bind the sugar chains of CSPGs with high affinity ([@R12]).

Both CSPGs and HSPGs are the ligands of PTPσ in nervous system with a similar binding affinity. Crystallographic analysis suggests that CSPGs can prevent PTPσ dimerization ([Fig. 1B](#F1){ref-type="fig"}), while HSPGs induce PTPσ clustering ([@R15]; [@R14]). CSPGs and HSPGs share the same binding site of PTPσ in the first Ig-like domain and they compete for PTPσ binding, resulting in opposite effects on axon elongation. CSPGs inhibit axon outgrowth in neurons derived from wild-type mice, but this effect is diminished in PTPσ-deficient neurons ([@R22]; [@R72]; [@R74]; [@R91]). In contrast, HSPGs dramatically promote axon outgrowth in wild-type, but not PTPσ-deficient neurons. Therefore, the CSPGs/HSPGs ratio is critical for determining PTPσ dimerization status in regulating axon growth. However, some issues remain regarding the interactions between proteoglycans and RPTPs. The CS-C GAG chain used in previous study ([@R14]) did not bind to PTPσ ([@R17]). Recently, Geller's group found that the fourth FNIII-containing domain of PTPσ alone could bind to HSPG heparin independently of three Ig domains, but not to CS-E or dermatan sulfate ([@R38]). It will be interesting to further study detailed mechanisms for interactions between CSPGs/HSPGs and PTPσ and potential role of the newly-identified binding domain of PTPσ for heparin.

Several other studies further support that PTPσ and LAR are important functional receptors for CSPGs. Newly-formed neurons from neuronal restricted precursors are intrinsically insensitive to CSPGs because low level expression of PTPσ and LAR. Several factors secreted by cultured neuronal and glial restricted precursors decrease CSPG inhibition and stimulate axon growth *in vitro* ([@R40]). Both PTPσ and LAR are expressed selectively in bad-regenerating neurons and have overlapping cellular distributions in Lamprey, a type of jawless fish ([@R117]), indicating that PTPσ and LAR mediate poor intrinsic regenerative capacity of bad-regenerating neurons and also serve as functional receptors for CSPGs in non-mammals.

PTPσ and LAR mediate CSPG inhibitions through both convergent and divergent downstream pathways in neurons. Recently, we compared effects of PTPσ and LAR on the activities of multiple signaling molecules using cultures of a neuronal cell line (Neuro-2A) to over-express these receptors and primary cultures of postnatal cerebellar neurons derived from knockout mice ([@R20]; [@R63]). PTPσ and LAR employ a few signaling pathways commonly, including RhoA, Akt, extracellular signal-regulated kinase (Erk) and microtubule- associated protein 1B (MAP1B). Their actions in transmitting CSPG effects to inhibit axon growth also involve distinct signal molecules, including the use by PTPσ of collapsing response mediator protein 2 (CRMP2, [Fig. 1B](#F1){ref-type="fig"}), adenomatous polyposis coli (APC), S6 ribosomal protein (S6) and cAMP response element-binding protein (CREB), whereas the use by LAR of cofilin, protein kinase Cζ (PKCζ) and liver kinase B1 (LKB1). Consistent with these results, deletion of both PTPσ and LAR showed additive effects in enhancement of axon growth in adult neurons *in vitro*. Thus, several intracellular signaling pathways are known to mediate CSPG actions through the RPTP receptors.

Previous reports also suggest that CSPGs use diverse pathways to suppress neuronal growth, including glycogen synthase kinase 3β (GSK3β) and PKC ([@R18]; [@R67]). Cultured axons contain transcripts encoding RhoA and applying CSPGs to axon compartment enhanced axonal RhoA synthesis ([@R98]). Inhibition of RhoA transcripts in axons increased their growth in the presence of CSPGs. Treatment of neurons with LAR inhibitory peptides or deletion of PTPσ elevated both Erk and Akt activities ([@R72]; [@R106]). In spite of recent progress in understanding intracellular signals of CSPGs, further studies are required to clarify some issues remained. For examples, Rho/Rock pathways inhibit both cofilin and CRMP2, but only PTPσ inhibits CRMP2 whereas only LAR inhibits cofilin ([@R63]). Likewise, mTOR/S6 and CREB are activated by Akt and Erk, but only PTPσ inhibits S6 and CREB signaling pathways.

5. PTPσ regulates functions of immune cells and development of autoimmune diseases {#S5}
==================================================================================

PTPσ is expressed by immune cells and has important functions in the immune system ([Fig. 2](#F2){ref-type="fig"}). PTPσ, but not LAR and PTPδ, is expressed in human pDCs controlled by transcription factor E2--2 ([@R9]). PTPσ is rapidly downregulated by pDC activation and its deficiency induces production of interferon α (IFNα) in pDCs. Antibody-mediated forced PTPσ activation inhibited Toll-like receptor 9-mediated pDC activation. pDCs can secrete type I IFN (IFNα or β) rapidly and abundantly in response to various stimuli and regulate viral infections through virus-specific T-cell responses. Accordingly, hyper-activation of pDCs is implicated in several autoimmune diseases, including inflammatory bowel disease ([@R13]; [@R25]; [@R85]). DC-specific deletion of PTPσ in mice with a LAR null background leads to IFN production by pDCs, leukocyte infiltration and mild spontaneous colitis ([@R9]). Consistently, three single nucleotide polymorphisms (SNPs) in human PTPRS (PTPσ) gene have been linked to ulcerative colitis, an inflammatory bowel disease characterized by dysregulation of auto-immune responses ([@R59]). PTPσ normally functions as a positive regulator of intestinal epithelial barrier by orchestrating epithelial cell adhesion through targeting of adherens junction proteins, including E-cadherin, β-catenin and ezrin ([@R60]). Together, PTPσ is essential to balance DC tyrosine phosphorylation mediated by various kinases ([@R23]) and to inhibit tyrosine phosphorylation-dependent pDC activation, spontaneous IFN production and immune-mediated intestinal inflammation.

We recently identified critical role of PTPσ in regulating auto-immune disorders in the nervous system and extended the function of PTPσ in immune system ([@R64]). We demonstrate that transgenic deletion or pharmacological inhibition of PTPσ significantly exacerbates clinical symptoms and axon/myelin damages in the spinal cord of mice with experimental autoimmune encephalomyelitis (EAE), a widely-used model for multiple sclerosis (MS). Following immunization with myelin oligodendrocyte glycoprotein (MOG) peptide, PTPσ knockout mice showed pro-inflammatory responses in the spinal cord and lymphoid organs by changing expression levels of various inflammatory-related genes, including specific cytokines (*Ifng* and *Il17a*) and chemokines (*Ccl2*, *Ccl5* and *Cxcl10*) ([@R64]). Interestingly, PTPσ deficiency stimulated activation of conventional DCs (cDCs), affected differentiation of CD4+ T lymphocytes directly, reduced number of regulatory T (Treg) cells, and facilitated infiltration of T cells and activation of macrophages and microglia in the CNS ([Fig. 2](#F2){ref-type="fig"}). Moreover, adoptive transfer of PTPσ-deficient cDCs stimulated with lipopolysaccharide to wild-type mice augmented EAE clinical symptoms following pulsed MOG~35--55~ peptide immunization. PTPσ deletion also enhanced expression of genes mediating immune responses, including Tbx21 in Th1 and Rorc in Th17 cells ([@R64]). Consistently, PTPσ deficiency has been reported to reduce expression level of Foxp3, a lineage-specific marker for Treg ([@R21]; [@R120]), which delay the onset of spontaneous EAE ([@R54]). Therefore, PTPσ is an important negative regulator for activation of pro-inflammatory responses of cDCs, differentiation of CD4+ T cells into Th1 and Th17 cells, and development of a CNS autoimmune disease. Notable, it is interesting to determine whether PTPσ directly regulates function of myelinating glia. PTPζ (PTPRZ), a member in the RPTP family, plays a negative role in oligodendrocyte differentiation during CNS development and remyelination in demyelinating CNS diseases by increasing apoptosis of mature oligodendrocytes ([@R32]; [@R44]).

PTPσ appears to regulate immune responses as a receptor of various immune cells by mediating constitutive signaling derived from the ECM ligands. The upstream signaling and physiological ligands that modulate PTPσ activity in immune cells or other cell types remain to be defined. HSPGs, the known ligands of RPTPs, have been reported to inhibit IFN production by macrophages in atherosclerosis mouse model ([@R28]). Syndecan-1, a HSPG, could suppress various inflammatory responses and EAE development in mice and its deficiency exacerbated disease symptoms and impaired recovery in EAE mice ([@R116]). In contrast, inhibition of CSPGs (also recognized ligands for RPTPs, but distinct type of proteoglycans from HSPGs) may become a therapeutic approach for autoimmune disease of MS. CSPGs are upregulated around the edge of MS lesions, whereas reduced in the center of active and chronic inactive plaques ([@R83]). Treatment with disaccharidic degradation product of CSPGs significantly alleviated clinical symptoms in EAE mice through reducing IFNγ and TNFα production by splenocytes ([@R71]; [@R118]). Moreover, some cytokines, such as IFNγ and TGFβ1, could alter the expression level of CSPGs ([@R24]; [@R78]).

Also as a member of type IIa RPTPs, LAR is expressed during a certain stage of thymocyte development, but not in B cells. The physiological function of LAR in immune system remains controversial. One study indicates that the phosphatase activity of LAR is not required for T-cell development, repertoire selection and function ([@R90]), but the other group reported that LAR deficiency affected differentiation and expansion of immature thymocytes as well as negative and positive selection ([@R43]). Moreover, T-cell receptor stimulation in response to calcium was significantly lower in thymocytes from LAR knockout mice, suggesting that LAR modulates T-cell receptor signaling for thymocyte differentiation.

6. PTPσ is a therapeutic molecular target for CNS injury and autoimmune disorders {#S6}
=================================================================================

Surmounting potent inhibition by CSPG-rich scar and its receptor-mediated downstream signaling is an important therapeutic target for achieving successful axon regeneration and functional recovery after CNS injuries. So far, the main *in vivo* therapeutic approach to overcome inhibition of CSPGs is enzymatic digestion with local application of ChABC. However, several disadvantages may prevent using this enzyme as a therapeutic choice for patients. ChABC cannot completely digest GAG chains from core glycoproteins and may leave undigested carbohydrate side chains on the molecules, which though less potent are still inhibitory ([@R51]). ChABC loses its enzymatic activity rapidly at body temperature and cannot cross the blood brain barrier. A group attempted to generate the thermostabilized ChABC ([@R50]). A single local application could not be sufficient to overcome the inhibition due to continuous generation of CSPGs after injury. Bacterial ChABC may also induce autoimmune reactions after pulsed injections. Therefore, new strategies to overcome inhibitory effects by CSPGs are required to facilitate CNS axon regeneration and functional recovery. An alternative approach to overcome scar-sourced inhibition is to design novel compounds that block functions of CSPGs or their receptors, including PTPσ.

In contrast to invasive approach of applying ChABC locally, systemic administration of peptides, antibodies and chemicals could block CSPG inhibition efficiently. A peptide (called intracellular PTPσ peptide, ISP) mimetic of the catalytic domain of PTPσ could overcome CSPG inhibition efficiently. Systemic treatment with ISP enhanced serotonergic axon regrowth and facilitated functional recovery of locomotor and urinary systems in rat with contusive SCI ([@R49]). Previously, we demonstrated that peptide antagonists for LAR reduced CSPG inhibition *in vitro* and increased descending serotonergic axon growth and promoted sustained locomotor recovery in SCI mice after systemic administration ([@R20]). Consistently, silencing PTPσ with lentivirus-mediated RNA interference promoted axon regeneration, synapse formation, and recovery of motor and sensory functions without affecting scar formation in rats with contusion SCI ([@R119]). Because PTPσ dimerization suppresses its phosphatase activity and CSPGs activate PTPσ by preventing it from dimerizing after binding as ligands, the approach to induce and stabilize PTPσ dimerization could be effective for blocking its function. Indeed, a new PTPσ IgG monoclonal antibody could induce PTPσ dimerization and promote neurite outgrowth in SH-SY5Y cells, a neuroblastoma cell line ([@R104]). Recently, a novel CSPG inhibitor, fluorosamine (peracetylated 4-fluorinated analog of glucosamine) has been shown to reduce CSPG contents and to promote process outgrowth and differentiation in oligodendrocyte precursor cells, thus accelerating re-myelination after focal CNS demyelination in mice ([@R39]). Therefore, blocking CSPGs, their receptors, or CSPG-receptor interactions could overcome scar-mediated growth inhibitions and promote functional recovery after CNS injury. Given that multiple factors contribute to the repair failure after CNS injury, combing CSPG signaling blockade with other strategies, such as cell transplantation, is likely to be more effective.

Suppressing DC activation mediated by PTPσ may become an attractive immunotherapy for several immune diseases. PTPσ act as an inhibitory receptor on DCs that prevents DC hyperactivation, subsequent IFN production, and autoimmune related inflammation. pDC hyperactivation occurred in inflammatory bowel disease ([@R4]) and in colitis associated with Wiskott-Aldrich syndrome ([@R68]). Increased numbers of cDCs and pDCs accumulated in the cerebrospinal fluid and white matter of MS patients ([@R47]; [@R68]) and abnormalities in DCs have been associated with several stages of MS related disorders. Because PTPσ is important for suppressing immune and autoimmune responses mediated by pDCs, cDCs, CD4+ T lymphocytes and other cells, and its suppression contributes to various immune-related diseases, such as EAE and spontaneous mild colitis ([@R9]; [@R64]), selective activation of this signaling protein may become an effective strategy for treating autoimmune related disorders.

Both PTPσ and its ligands, such as CSPGs, may become molecular targets for treating MS related disorders and other immune diseases. Any approaches that block PTPσ dimerization might activate this phosphatase and reduce overactivation of immune cells. Treatment with the disaccharide degradation product of CSPG (CSPG-DS), a CSPG derivative, significantly decreases production of IFNγ by brain-in-filtrating lymphocytes in EAE mice ([@R71]; [@R118]). CSPG-DS treatment also markedly alleviated the clinical symptoms of EAE by reducing infiltrating T cells and activated microglia. In contrast, treatment with CS-A, a complete CS GAG chain unattached to proteoglycans, exacerbated EAE symptoms and increased infiltrated T cells in the CNS and their differentiation into pathogenic types of Th1 and Th17 ([@R118]). It is interesting to dissect the precise mechanisms for CSPG-DS and CS-A to regulate EAE development and whether PTPσ mediates these effects although CS-A does not bind PTPσ ([@R17]).

7. Prospective {#S7}
==============

PTPσ plays important physiological and pathological roles in the nervous system of mammalians during development and in adults. PTPσ and other type IIa RPTPs are expressed in presynaptic terminals and make trans-synaptic adhesion complexes with post-synaptic adhesion molecules to organize synapse development and to modulate placidity of mature neurons, including learning and memory. Importantly, PTPσ, as well as LAR, functions as important receptors for CSPG inhibitors generated by reactive scar tissues. On the other hand, PTPσ is expressed by various immune cells, especially pDCs, cDCs and CD4+ T cells, and plays crucial roles for regulating immune responses and development of autoimmune diseases, including EAE. The tremendous advances in our understanding of PTPσ functions provide opportunity for developing effective therapeutic strategies for the disorders associated with dysfunctions of PTPσ and its related genes. Because of the diverse regulatory roles of PTPσ in different tissue systems, this phosphatase may become an important target for treating a number of human diseases, such as CNS injuries, MS and other autoimmune diseases. However, it seems important to develop effective approaches to target PTPσ and its signaling pathway selectively. For example, PTPσ suppression may have beneficial effects in the nervous system by promoting axon regeneration and neural repair, but it may also result in damaging roles in the other systems, such as inducing DC hyper-activation and autoimmune responses. Moreover, it is very important to further characterize functions of PTPσ and related molecules, and their detailed cellular and molecular mechanisms in various cell types. Better understanding physiology and pathophysiology of PTPσ-associated genes is likely to felicitate development of highly effective therapies for various neurological and autoimmune diseases.
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![PTPσ is important to regulate synapse formation by interacting with several postsynaptic proteins (A) and to mediate CSPG inhibition of neuronal growth as a receptor through multiple intracellular pathways (B). (A) PTPσ is localized to the growth cone at axonal tip in immature neurons during development and serves as a presynaptic hub by interacting with diverse postsynaptic partners, including NGL-3, TrkC, IL1RAcP and Slitrks, thus regulating the synapse formation in developmental neuron. (B) PTPσ can bind both HSPGs and CSPGs. Binding with the former induces PTPσ clustering and inactivation, promoting axon growth. In contrast, binding with CSPGs prevents PTPσ dimerization and activates this receptor and its downstream signaling pathways, inhibiting axon growth after CNS injury. Intracellularly, activation of PTPσ by CSPGs activate RhoA-Rock signaling and inactivate Akt and Erk pathways. Activation and/or inactivation of these signaling pathways mediate CSPG inhibition by other downstream signaling molecules, including GSK3β, CRMP2, APC, MAP1B, mTOR and CREB. Ig-like: immunoglobulin-like domains; FN-III: fibronectin type III domain; D1: D1 catalytic domain; D2: D2 non-catalytic domain.](nihms954711f1){#F1}

![PTPσ inhibits activation of immune cells and development of autoimmune diseases, including colitis and EAE. PTPσ deficiency induces activation of DCs (cDC and pDC), differentiation of CD4+ T cells into specific Th1 and Th17 cells, infiltration of leukocytes and generation of pro-inflammatory related cytokines including IFN. Thus, PTPσ inhibition facilitates development of autoimmune diseases, such as colitis and CNS autoimmune demyelinating disease EAE.](nihms954711f2){#F2}
